<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[m. e. garza Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/m.+e.+garza.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to m. e. garza]]></description>
	<s:counts start="0" returned="20" found="30" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Novelos CEO: Very Bullish About Upcoming Pivotal Phase III Results]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F178658-novelos-ceo-very-bullish-about-upcoming-pivotal-phase-iii-results%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[We have just begun covering what may become one of the big small cap winners of 2010. The drug candidate is attracting unsolicited attention from news media outlets and Purdue Pharma (of OxyContin® fame), who is making a concerted push in cancer treatments and recently completed a $9M private placement...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 17 Dec 2009 06:04:20 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
	</item>
	<item>
		<title><![CDATA[CytRx Corporation: A Solid Rebound Play?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F176288-cytrx-corporation-a-solid-rebound-play%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[As anticipated and reported by BioMedReports on Novermber 23rd, CytRx Corporation (NASDAQ:CYTR) appears to be shaping up into quite a rebound story. Yesterday morning, officials at the company have announced that they are permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 03 Dec 2009 12:53:06 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/cytrx+corp..html"><![CDATA[CytRx Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CYTR</category>
		<category domain="tickers">CYTR</category>
	</item>
	<item>
		<title><![CDATA[CytRx Announces First of Two Positive Developments Ahead]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175426-cytrx-announces-first-of-two-positive-developments-ahead%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Just as readers of BioMedReports were told on Monday, CytRx Corporation (NASDAQ:CYTR) announced the first of two key news developments for the company on Tuesday. See the Reuters Story here. by M. E. Garza]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 26 Nov 2009 02:17:07 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/cytrx+corp..html"><![CDATA[CytRx Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CYTR</category>
		<category domain="tickers">CYTR</category>
	</item>
	<item>
		<title><![CDATA[SIGA Shares Could Double on Pending Government News]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175419-siga-shares-could-double-on-pending-government-news%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[BioMedReports has learned that shares of this bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents, such as smallpox and arenaviruses is expecting big news and government orders.Our Subscribers were alerted Monday that a series of big government orders are...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 26 Nov 2009 01:50:37 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/siga+technologies+inc..html"><![CDATA[SIGA Technologies Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SIGA</category>
		<category domain="tickers">SIGA</category>
	</item>
	<item>
		<title><![CDATA[CytRx Corporation: Key Developments Ahead]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175035-cytrx-corporation-key-developments-ahead%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The clouds of darkness that have been hanging over CytRx Corporation (NASDAQ:CYTR), may soon be cast aside. The stock, which has traded as low as $.24 earlier this year, appears to be on the rebound with at least two key developments on the horizon.On Friday morning, after seeing the stock...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 24 Nov 2009 05:25:15 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/cytrx+corp..html"><![CDATA[CytRx Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CYTR</category>
		<category domain="tickers">CYTR</category>
	</item>
	<item>
		<title><![CDATA[Law Firms Going After Hemispherx]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F173314-law-firms-going-after-hemispherx%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Accusations are heating up in the drama involving Hemispherx Biopharma, Inc (AMEX:HEB) and the law firms trying to go after the well capitalized biotech on behalf of investors. The latest of several law firms to jump on the company is led by Former Attorney General of Louisiana Charles C. Foti,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 13 Nov 2009 02:01:42 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/hemispherx+biopharma+inc..html"><![CDATA[Hemispherx BioPharma Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HEB</category>
		<category domain="tickers">HEB</category>
	</item>
	<item>
		<title><![CDATA[Why Has Cel-Sci Quietly Amended Some Previously Filed Paperwork?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F172968-why-has-cel-sci-quietly-amended-some-previously-filed-paperwork%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Is the management at CEL-SCI Corporation CVM signaling that something big is coming? In mid September, on the same day that CEL-SCI Corporation announced that the U.S. Food and Drug Administration FDA had indicated that the company could proceed with its first clinical trial to evaluate the effect of its...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 12 Nov 2009 02:21:52 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/biocryst+pharmaceuticals+inc..html"><![CDATA[BioCryst Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/cel-sci+corp..html"><![CDATA[CEL-SCI Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BCRX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CVM</category>
		<category domain="tickers">BCRX,CVM</category>
	</item>
	<item>
		<title><![CDATA[Transformative Times for BioSante Pharmaceuticals]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F167782-transformative-times-for-biosante-pharmaceuticals%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA["The last 75 days have been transformative for BioSante," Bill Milling, Sr. Dir Operations for BioSante Pharmaceuticals, Inc. BPAX told BioMedReports.  Yesterday, the company announced positive safety data in its ongoing  LibiGel Phase III clinical development program. "First we closed a financing in August having raised $12 million,"...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 21 Oct 2009 02:09:08 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/biosante+pharmaceutical+inc..html"><![CDATA[Biosante Pharmaceutical Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/cell+genesys+inc..html"><![CDATA[Cell Genesys Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BPAX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEGE</category>
		<category domain="tickers">BPAX,CEGE</category>
	</item>
	<item>
		<title><![CDATA[Epix Surrenders Battle to Keep Alzheimer's Program Afloat]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F167303-epix-surrenders-battle-to-keep-alzheimer-s-program-afloat%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Even as they were announcing their FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patients, EPIX Pharmaceuticals, Inc. (OTC:EPIX) plans quietly to wind down operations after a hard fought battle to keep the company afloat. The Lexington, Mass.-based company&#8217;s officials said...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 19 Oct 2009 07:26:37 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/epix+pharmaceuticals+inc..html"><![CDATA[EPIX Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">EPIX</category>
		<category domain="tickers">EPIX</category>
	</item>
	<item>
		<title><![CDATA[Stage Set for Acorda Bounce?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F165895-stage-set-for-acorda-bounce%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Shares of Acorda Therapeutics Inc. (NASDAQ:ACOR) have hit a five month low, after documents posted on the U.S. Food and Drug Administration's Website show that some agency investigators have questioned whether Acorda's proposed MS treatment Fampridine-SR should be approved. As subscribers to the BioMedReports FDA Calendar know, a special panel...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 11 Oct 2009 03:37:25 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/acorda+therapeutics+inc..html"><![CDATA[Acorda Therapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACOR</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">ACOR,BIIB</category>
	</item>
	<item>
		<title><![CDATA[Cel-Sci's Positive Momentum Keeps Building]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F162010-cel-sci-s-positive-momentum-keeps-building%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[For years, it seems, CEL-SCI's CVM investors have been waiting for this perfect storm of positive developments.   The company was so badly beaten and on the ropes recently, that most of the management team continued to work, for extended periods of time, without compensation. "When I came home...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 17 Sep 2009 06:52:11 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/cel-sci+corp..html"><![CDATA[CEL-SCI Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/novavax.html"><![CDATA[Novavax]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CVM</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVAX</category>
		<category domain="tickers">CVM,NVAX</category>
	</item>
	<item>
		<title><![CDATA[Cloak and Dagger Developments at Cel-Sci Against Swine Flu]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F161954-cloak-and-dagger-developments-at-cel-sci-against-swine-flu%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[&#8220;The Obama administration is very worried that this could turn into a double dip double bottom recession,&#8221; said one person familiar with this situation. &#8220;They are doing everything they can to ensure that the H1N1 pandemic is not the catalyst for just such an event.&#8221;    As I...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 17 Sep 2009 02:50:53 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/cel-sci+corp..html"><![CDATA[CEL-SCI Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CVM</category>
		<category domain="tickers">CVM</category>
	</item>
	<item>
		<title><![CDATA[Spectrum Pharma: Market Opportunities for Zevalin May Expand Significantly]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F161243-spectrum-pharma-market-opportunities-for-zevalin-may-expand-significantly%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Following the presentation by Spectrum Pharmaceuticals SPPI, which was held in front of a standing room only crowd of institutional investors, hedge fund managers and Wall Street banker types at the Rodman & Renshaw Healthcare Conference in New York, Dr. Andrew Sandler was mobbed with questions from members of the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 13 Sep 2009 01:11:08 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/spectrum+pharmaceuticals+inc..html"><![CDATA[Spectrum Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SPPI</category>
		<category domain="tickers">SPPI</category>
	</item>
	<item>
		<title><![CDATA[Salix Pharma Continues to Rise in Anticipation of FDA Decision]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F160201-salix-pharma-continues-to-rise-in-anticipation-of-fda-decision%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Shares of Salix Pharmaceuticals (NASDAQ:SLXP) have been rising in anticipation of their upcoming FDA decision, which is due this coming week. Shares for the company rose as much as 34% since July and on September 11, the FDA is scheduled to decide whether or not to approve the company's Metozolv...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 06 Sep 2009 06:15:43 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/salix+pharmaceuticals+ltd..html"><![CDATA[Salix Pharmaceuticals Ltd.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SLXP</category>
		<category domain="tickers">SLXP</category>
	</item>
	<item>
		<title><![CDATA[EpiCept Is on the Move]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F159980-epicept-is-on-the-move%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Shares of EpiCept (NASDAQ: EPCT) are on the move as speculation about coming news had shares trading up more than 21% on Wednesday and even higher overnight in Europe where shares for the company are also traded on the NASDAQ OMX Nordic Exchange on Thursday morning. The Company possesses an...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 04 Sep 2009 02:57:07 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/epicept+corp..html"><![CDATA[EpiCept Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">EPCT</category>
		<category domain="tickers">EPCT</category>
	</item>
	<item>
		<title><![CDATA[Allos Therapeutics: Prospects for FDA Approval of Folotyn Are Healthy]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F159976-allos-therapeutics-prospects-for-fda-approval-of-folotyn-are-healthy%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[After announcing  that  the U.S.       Food and Drug Administration&#8217;s [FDA] Oncologic Drugs Advisory Committee [ODAC] voted 10-4 that the response rate and duration of response       observed with FOLOTYNTM pralatrexate are reasonably likely to predict clinical benefit...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 04 Sep 2009 02:47:45 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/allos+therapeutics+inc..html"><![CDATA[Allos Therapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ALTH</category>
		<category domain="tickers">ALTH</category>
	</item>
	<item>
		<title><![CDATA[Spectrum Pharmaceuticals, Sequenom Shares Rise on Heavy Volume]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F159335-spectrum-pharmaceuticals-sequenom-shares-rise-on-heavy-volume%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) jumped  on twice the average volume Monday. Shares for the biopharmaceutical company, which focuses on pioneering novel cancer therapies with a focus primarily in the areas of hematology-oncology and urology, are under a heavy accumulation which is related to Spectrum&#8217;s dealings with the FDA,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 01 Sep 2009 02:53:07 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/spectrum+pharmaceuticals+inc..html"><![CDATA[Spectrum Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sequenom+inc..html"><![CDATA[Sequenom Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SQNM</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SPPI</category>
		<category domain="tickers">SQNM,SPPI</category>
	</item>
	<item>
		<title><![CDATA[Cel-Sci Thrives With New Manufacturing Facility]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F158141-cel-sci-thrives-with-new-manufacturing-facility%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[New details have begun to emerge about Cel-Sci Corporation's CVM new, state-of-the-art "Cold-Fill" manufacturing facility which will not only be used to manufacture Multikine® the world's first immunotherapeutic agent (which is being developed as a first-line standard of care treatment for cancer) for both the Phase III trials and commercial...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 25 Aug 2009 05:47:09 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/cel-sci+corp..html"><![CDATA[CEL-SCI Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CVM</category>
		<category domain="tickers">CVM</category>
	</item>
	<item>
		<title><![CDATA[CEL-SCI CEO's Bullish Biotech Play]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F157743-cel-sci-ceo-s-bullish-biotech-play%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[CEL-SCI's CVM CEO is suddenly feeling more confident than ever.   Who can blame him?   There are verified reports that the company's biotechnology activates the immune system and targets the H1N1 flu's hemagglutinin molecule. The treatment apparently induces a defined immune response which could help infected swine...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sun, 23 Aug 2009 05:24:44 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/cel-sci+corp..html"><![CDATA[CEL-SCI Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CVM</category>
		<category domain="tickers">CVM</category>
	</item>
	<item>
		<title><![CDATA[Oculus's New Product Can Tap into Several Billion Dollar Markets]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F157609-oculus-s-new-product-can-tap-into-several-billion-dollar-markets%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[This is not your typical biotech story. This is not a company waiting for a phase three study or an FDA decision in order to become profitable. This is now a commercial story with a company that is being very aggressive in their pursuit of additional revenues and a solid...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 21 Aug 2009 11:22:07 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/m.+e.+garza.html"><![CDATA[M. E. Garza]]></category>
		<category domain="http://resources.bnet.com/topic/oculus+innovative+sciences+inc..html"><![CDATA[Oculus Innovative Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">OCLS</category>
		<category domain="tickers">OCLS</category>
	</item>
</channel>
</rss>
